ArticleThe oncologist2025

Complete response following trastuzumab-deruxtecan in a man with HER2-overexpressing metastatic, poorly differentiated scrotal carcinoma.

Mia Hofstad et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.